Previous 10 | Next 10 |
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
– Management will discuss lirentelimab development and Allakos pipeline – REDWOOD CITY, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002)...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Allakos (NASDAQ: ALLK) is a clinical-stage biopharmaceutical company that recently saw a pretty dramatic price collapse at the end of December. I believe that ALLK stock, and its subsequent collapse, is a learni...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips As recently shown, investing in Allakos (NASDAQ: ALLK ) proves the inherent danger within the biopharmaceutical sector. After reaching a 52-week high of more than $157, ALLK stock plunged late in December and now...
Allakos (NASDAQ: ALLK) stock sank 87.5% in December, according to data from S&P Global Market Intelligence . The clinical-stage biotech company's share price plummeted after the publication of disappointing trial data for its key treatment. ALLK data by ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Based in California, clinical-stage biopharmaceutical company Allakos (NASDAQ: ALLK ) develops therapeutic antibodies for allergic, inflammatory and proliferative diseases. For folks who can tolerate volatility...
Allakos (NASDAQ:ALLK) down 3% premarket after H.C. Wainwright analyst Patrick Trucchio lowered the firm's price target (PT) on the stock to $20 from $230; keeps Buy rating. Last week, the company announced disappointing top-line data from late-stage studies of lirentelimab in patien...
The meme stock frenzy powered by retail investors has dominated this year's investing world. Several WallStreetBets (WSB) stocks have risen solely based on investors’ sentiment irrespective of their fundamentals and growth prospects. So, it could be wise to avoid fundamentally weak mem...
Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available on Seeking Alpha, iTunes, Stitcher and Spotify. U.S. stock indexes closed higher ahead of the Christmas break with the S&P 500 carving out a new high. Investors took a generally positive stance on t...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
News, Short Squeeze, Breakout and More Instantly...
– AK006 achieved serum concentrations consistent with levels demonstrating inhibitory activity in preclinical experiments – – Skin biopsies from subjects treated with AK006 show high receptor occupancy – – AK006 was well-tolerated with a favorable safety pro...
– Top-line Phase 1 CSU results expected at year end 2024 – SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK006 for the treatment of mast cell-driven diseases, today announced that the first patient with chr...
SAN CARLOS, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for...